Supplement
Beta Glucan
Discover the science-backed potential of beta glucan as an adjunct in cancer therapy. This post delves into the latest research
Click 
Fucoidan, a fucose-rich sulphated polysaccharide derived from brown seaweed, has garnered significant attention for its potential anti-cancer properties. Research spanning in vitro cell studies, animal models, and mechanistic investigations highlights several ways in which fucoidan may exert anti-tumour effects.
Key Anti-Cancer Mechanisms of Fucoidan
Induction of Apoptosis: Fucoidan has been shown to trigger programmed cell death (apoptosis) in various cancer cell lines, including breast, colon, lung, and liver cancers. This is achieved through mitochondrial pathways, involving the downregulation of anti-apoptotic proteins (e.g., Bcl-2, Survivin), upregulation of pro-apoptotic factors (e.g., Bax), release of cytochrome C, and activation of Caspase-331. These molecular events collectively lead to the destruction of cancer cells while sparing normal cells3.
Inhibition of Angiogenesis: Tumour growth and metastasis rely heavily on the formation of new blood vessels (angiogenesis). Fucoidan interferes with this process by inhibiting the binding of vascular endothelial growth factor (VEGF) to its cellular receptors, thereby reducing the supply of oxygen and nutrients to tumours13. Animal studies have confirmed reduced angiogenesis and tumour necrosis following fucoidan treatment23.
Suppression of Metastasis: Preclinical models indicate that fucoidan can reduce the spread of cancer, particularly the metastasis of breast cancer cells to the lungs. This effect is at least partly due to the downregulation of VEGF and other signalling pathways involved in tumour cell migration and invasion3.
Immunomodulation and Anti-Inflammatory Effects: Fucoidan modulates the immune response, enhancing the activity of natural killer (NK) cells and reducing pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α. This contributes to its anti-tumour efficacy and may help counteract the immunosuppressive environment often found in cancer21.
Low Toxicity to Normal Cells: Unlike many conventional chemotherapeutic agents, fucoidan demonstrates minimal toxicity to healthy tissues in animal models, making it a promising candidate for adjunctive cancer therapy23.
Structural Features Influencing Anti-Cancer Activity
The anti-cancer efficacy of fucoidan is closely linked to its structural characteristics:
Molecular Weight: Lower molecular weight fucoidan exhibits enhanced bioavailability and greater interaction with cancer cells, resulting in stronger anti-tumour effects2.
Degree of Sulphation: Higher levels of sulphation increase fucoidan’s solubility and bioactivity, facilitating its interaction with cellular receptors involved in cancer progression2.
Monosaccharide Composition: The presence of L-fucose is particularly important for anti-cancer activity, as it aids in the recognition and binding to cancer cell receptors2.
Preclinical Evidence
In a mouse model of hepatocellular carcinoma, fucoidan isolated from Saccharina japonica inhibited tumour growth by 42.93% without noticeable toxicity, significantly reduced angiogenesis, and lowered serum tumour markers2.
In breast cancer models, fucoidan reduced tumour volume and weight, promoted apoptosis, and inhibited lung metastasis, all without affecting the proliferation of normal cells3.
Clinical Potential and Future Directions
While the preclinical evidence for fucoidan’s anti-cancer activity is robust, clinical trials in humans remain limited1. Fucoidan’s ability to synergise with conventional chemotherapy and protect against treatment-related toxicity is of particular interest for future research and clinical application12. Further studies are needed to clarify optimal dosing, bioavailability, and efficacy in diverse cancer types and patient populations.
| Mechanism | Evidence/Effect | Reference |
|---|---|---|
| Induction of apoptosis | Downregulation of Bcl-2, activation of Caspase-3 | 13 |
| Inhibition of angiogenesis | Blocks VEGF binding, reduces blood vessel formation | 123 |
| Suppression of metastasis | Reduces VEGF, inhibits cell migration and invasion | 3 |
| Immunomodulation | Enhances NK cells, lowers IL-1β, IL-6, TNF-α | 21 |
| Low toxicity | Minimal impact on normal cells and body weight in mice | 23 |
Fucoidan stands out as a multifunctional, low-toxicity natural compound with demonstrated anti-cancer properties in preclinical studies. Its mechanisms—apoptosis induction, angiogenesis inhibition, metastasis suppression, and immune modulation—make it a promising adjunct or alternative in cancer therapy, pending further clinical validation123.
No official, universally established dosage for fucoidan exists, as it is not approved as a drug by regulatory authorities. However, clinical research and expert consensus provide guidance on safe and effective dosing, especially in the context of cancer and adjunctive therapy.
Clinical and Research-Based Dosage Ranges:
For cancer and serious illnesses: Multiple clinical studies and expert sources recommend a daily intake of 3 to 6 grams of fucoidan to support cancer therapy or serious disease management161417. This dosage is typically divided into several doses throughout the day (e.g., morning, noon, evening, and before bedtime) to optimise immune response19.
For general health or lifestyle-related diseases: A lower dose of 1 to 2 grams per day is suggested for maintenance and prevention1.
Clinical trials: Studies in cancer patients have safely used doses up to 4.05 grams per day for periods ranging from several weeks to six months, with no significant adverse effects reported610121417. In one trial, patients received 4 grams twice daily (total 8 grams/day) as a supplement to chemotherapy, with good tolerability14.
Other conditions: Lower doses (e.g., 300 mg to 1,000 mg per day) have been used in studies for osteoarthritis and general supplementation, also demonstrating safety2510.
Safety Profile:
Fucoidan is generally well-tolerated, even at higher doses (up to 4 grams daily), with minimal side effects reported in clinical studies361012.
The most commonly reported side effect is mild gastrointestinal disturbance (e.g., diarrhoea), which resolves upon discontinuation10.
Caution is advised for individuals on anticoagulant therapy, as fucoidan may have blood-thinning properties510.
Summary Table: Clinical Dosage and Safety
| Use Case | Typical Dose (per day) | Duration | Safety Notes |
|---|---|---|---|
| Cancer therapy support | 3–6 grams | Weeks–months | Well-tolerated; monitor for GI symptoms |
| General health | 1–2 grams | Ongoing | Safe for most; consult healthcare provider |
| Osteoarthritis | 300–1,000 mg | 12 weeks | Safe at these doses |
| Clinical trials (high) | Up to 4.05 grams | Up to 6 months | No serious adverse effects reported |
Conclusion
While no official standard exists, 3–6 grams per day is a commonly recommended and clinically tested dosage for cancer support, with a strong safety record in published studies. As with any supplement, individuals should consult their healthcare provider before starting fucoidan, especially if taking other medications or managing chronic conditions.
Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer
Human clinical studies and preclinical research consistently demonstrate that fucoidan is very well tolerated, even at therapeutic doses used alongside chemotherapy for cancer patients.
Key Findings from Clinical Trials:
No Serious Adverse Effects: In multiple studies involving patients with advanced or unresectable cancers (colorectal and gastric), fucoidan administered at therapeutic doses (typically 3–6 grams per day or equivalent) was not associated with significant side effects. No cases of allergic dermatitis or severe toxicity attributable to fucoidan were reported, and all patients were able to complete their courses of fucoidan therapy safely25.
Gastrointestinal Tolerance: Mild gastrointestinal symptoms, such as diarrhoea, have occasionally been noted in the context of chemotherapy, but these were not significantly increased by fucoidan supplementation25.
Fatigue Reduction: Notably, fucoidan appears to reduce the occurrence and severity of chemotherapy-induced fatigue. In one study, the rate of moderate-to-severe fatigue dropped from 60% in the control group to 10–25% in the fucoidan group, suggesting a protective effect against this common side effect of cancer treatment25.
No Impact on Chemotherapy-Related Toxicities: Fucoidan did not significantly alter the rates of other chemotherapy-related adverse events such as neutropenia, anaemia, thrombocytopenia, nausea, stomatitis, or peripheral neuropathy25.
No Hepatic or Allergic Reactions: No liver dysfunction or allergic reactions were attributed to fucoidan in these studies25.
Drug Interaction Potential:
At higher doses, certain fucoidan extracts may have a limited potential to interact with hepatic metabolism pathways (e.g., CYP450 or COMT), but no clinically significant drug-supplement interactions have been reported in cancer patients to date3.
| Side Effect | Incidence with Fucoidan | Comments |
|---|---|---|
| Allergic reactions | None observed | Safe in all reported studies |
| Gastrointestinal upset | Rare, mild | Not significantly increased |
| Fatigue | Reduced | Protective effect seen |
| Myelosuppression | No increase | Similar to control |
| Hepatic dysfunction | None observed | |
| Drug interactions | Theoretical, rare | No clinical cases reported |
Fucoidan, when used at therapeutic doses for cancer (3–6 grams per day), is safe and well tolerated. It does not cause significant side effects and may even reduce the severity of chemotherapy-induced fatigue. Mild gastrointestinal symptoms are possible but uncommon, and no serious allergic or hepatic reactions have been observed. As with any supplement, patients should consult their healthcare provider before starting fucoidan, especially if taking multiple medications or undergoing intensive cancer therapy.
Fucoidan has been tested in combination with various conventional cancer therapies, both in laboratory studies and in human clinical trials.
Chemotherapy Combinations:
Fucoidan has been combined with standard chemotherapy regimens such as FOLFOX (oxaliplatin plus 5-fluorouracil/leucovorin), FOLFIRI (irinotecan plus 5-fluorouracil/leucovorin), and S-1 plus cisplatin in patients with advanced colorectal and gastric cancers. These studies found that fucoidan helped reduce the toxicity of chemotherapy—particularly fatigue and diarrhoea—allowing patients to continue treatment for longer periods. Some studies also reported a trend towards improved survival, although not always statistically significant25.
Synergy with Chemotherapy and Targeted Agents:
In breast cancer cell studies, fucoidan enhanced the effects of chemotherapeutic agents such as cisplatin, tamoxifen, and paclitaxel, increasing cancer cell death through modulation of apoptosis-related proteins and signalling pathways3.
In HER2-positive breast cancer cell lines, fucoidan combined with docetaxel or trastuzumab resulted in higher cytotoxic and apoptotic effects than either agent alone, without harming normal cells6.
Mechanisms of Synergy:
Fucoidan’s anti-cancer effects in combination therapies are thought to arise from its ability to:
Variable Effects with Targeted Therapy:
Not all combinations are universally synergistic. For example, when combined with the tyrosine kinase inhibitor lapatinib, fucoidan showed either synergistic or antagonistic effects depending on the cancer cell type, highlighting the need for further research into specific drug interactions37.
| Therapy Combined With | Cancer Type | Observed Effect | Reference |
|---|---|---|---|
| FOLFOX/FOLFIRI | Colorectal | Reduced fatigue, longer chemo duration | 25 |
| S-1 + Cisplatin | Gastric | Less diarrhoea/fatigue, prolonged treatment | 5 |
| Cisplatin, Tamoxifen, Paclitaxel | Breast | Enhanced cancer cell death | 3 |
| Docetaxel, Trastuzumab | HER2+ Breast | Increased cytotoxicity/apoptosis in cancer cells | 6 |
| Lapatinib | EGFR/ERBB2+ cancers | Synergistic or antagonistic, cell type dependent | 7 |
Fucoidan has demonstrated promising results as an adjunct to chemotherapy and targeted therapies, with evidence of reduced treatment toxicity, enhanced anti-cancer effects, and improved patient tolerance in several cancer types. However, the effect can vary depending on the specific drug and cancer context, and further clinical studies are warranted to optimise its use in combination regimens.
US National Library of Medicine research on Fucoidan
Clinical studies evaluating fucoidan as a supplement for cancer patients—particularly at therapeutic doses (typically 1–5 grams daily)—suggest that fucoidan is safe and may provide modest improvements in quality of life (QoL), especially in areas such as fatigue, chemotherapy side effects, and inflammation.
However, the evidence is mixed, and most benefits reported are either positive but not statistically significant or limited to specific patient subgroups.
1. Fatigue Reduction
Several studies report that fucoidan supplementation can reduce the frequency and severity of fatigue in cancer patients undergoing chemotherapy, particularly those with metastatic or recurrent colorectal cancer85.
One randomised trial found that patients receiving 4.05 g/day of high-molecular-weight fucoidan for six months experienced less fatigue during chemotherapy compared to controls8.
Other studies note reduced fatigue, but the effect often did not reach statistical significance due to small sample sizes or patient heterogeneity53.
2. Reduction of Chemotherapy Side Effects
Fucoidan may help reduce the incidence of certain chemotherapy-related adverse effects, such as diarrhoea, taste changes, and peripheral neuropathy, though these reductions are often not statistically significant54.
Some studies report a trend towards fewer side effects and improved tolerance of chemotherapy, allowing patients to stay on treatment longer54.
3. Inflammatory Markers and Immune Function
Fucoidan has demonstrated anti-inflammatory effects, including significant reductions in pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) after two weeks of supplementation36.
Improvements in immune parameters (such as increased CD19 lymphocyte populations) have also been observed, which may contribute to better overall well-being and resilience during therapy7.
4. General Quality of Life Scores
Most studies using validated QoL questionnaires (such as EORTC QLQ-C30) found that overall QoL scores either remained stable or showed slight improvement during fucoidan supplementation, even as patients continued chemotherapy73.
In one study, financial difficulty—a common QoL concern for cancer patients—was significantly improved in the fucoidan group, possibly due to reduced treatment-related complications or improved ability to continue working52.
5. Safety and Tolerability
Across studies, fucoidan at therapeutic doses is very well tolerated, with no significant increase in adverse effects compared to controls145.
There is no evidence of negative impact on liver or kidney function, and no reports of serious allergic reactions or toxicity45.
| QoL Domain | Observed Effect with Fucoidan | Strength of Evidence |
|---|---|---|
| Fatigue | Reduced frequency/severity | Moderate (some significance) |
| Chemotherapy side effects | Trend towards reduction | Weak to moderate |
| Inflammatory markers | Significant reduction | Moderate |
| General QoL scores | Stable or slight improvement | Weak to moderate |
| Financial difficulty | Significant improvement in some cases | Weak (limited studies) |
| Safety/tolerability | Excellent, no significant toxicity | Strong |
Many studies are small, non-blinded, or have heterogeneous patient populations, limiting the strength of conclusions.
QoL improvements are often positive but not always statistically significant.
Most robust data are in metastatic or recurrent colorectal and gastric cancer; less is known about other cancer types.
At therapeutic doses, fucoidan is safe and may modestly improve quality of life for cancer patients, particularly by reducing fatigue and some chemotherapy side effects, and by lowering inflammation. The most consistent benefit is reduced fatigue in patients undergoing chemotherapy for metastatic or recurrent colorectal cancer. While the evidence is encouraging, larger and more rigorous clinical trials are needed to confirm and clarify these effects for broader patient groups.
We’ve done our best to include as much information as possible for this supplement.
If you have any other questions, please send us a message or join our Skool Group and ask our knowledgeable and friendly community.
Fucoidan is generally available as a dietary supplement in the UK and other countries. It can be purchased online, in health food stores, and some pharmacies.
Current clinical evidence suggests that the patients most likely to benefit from fucoidan supplementation are those with metastatic or recurrent gastrointestinal cancers, particularly colorectal and gastric cancer. This conclusion is drawn from the majority of human studies and systematic reviews, which have focused on these populations156815.
Metastatic or Recurrent Colorectal and Gastric Cancer:
Most published clinical trials and systematic reviews have enrolled patients with metastatic or recurrent colorectal and gastric cancer. These studies indicate possible benefits such as longer survival time, improved disease control, reduced side effects from chemotherapy (notably fatigue), lower inflammatory markers, and better quality of life1567815.
Older Adults:
Clinical trial data show that both older (≥65 years) and younger adults (<65 years) with cancer have participated, and no significant differences in outcomes or adverse effects were observed between age groups5. This suggests fucoidan is generally well tolerated across adult age ranges.
Patients Undergoing Chemotherapy or Chemoradiotherapy:
Fucoidan appears to be especially beneficial for those receiving intensive treatments, as it may help maintain physical well-being, reduce fatigue, and support immune and nutritional status during therapy1357.
Other Cancers:
While there is some preclinical and limited clinical evidence for benefit in other cancer types (e.g., lung cancer7, bladder cancer9), the strongest and most consistent human data currently pertain to gastrointestinal cancers.
No Universal Guidelines:
There are currently no official clinical guidelines specifying which patient groups should use fucoidan, and the evidence base is limited by small sample sizes and study heterogeneity15.
Affordability:
Systematic reviews note that fucoidan should be recommended primarily for patients who can afford the expense, as it is not universally covered or subsidised1.
Need for Broader Research:
Further studies are needed to determine the benefits of fucoidan in other cancer types and in broader patient populations1.
| Patient Demographic | Evidence of Benefit | Notes |
|---|---|---|
| Metastatic/recurrent colorectal cancer | Strongest | Most clinical data available156815 |
| Metastatic/recurrent gastric cancer | Strongest | Most clinical data available156815 |
| Patients on chemotherapy/chemoradiotherapy | Moderate to strong | Improved QoL, reduced fatigue1357 |
| Older adults (≥65 years) | Well tolerated | No age-related increase in side effects5 |
| Other cancer types | Limited | Preclinical or small clinical studies79 |
Based on current evidence, fucoidan supplementation may be most beneficial for adults with metastatic or recurrent colorectal or gastric cancer, especially those undergoing chemotherapy or chemoradiotherapy. It is well tolerated across age groups, but broader research is needed to establish benefits in other cancers and patient populations.
No definitive, clinically validated resistance markers have been established for fucoidan’s anti-cancer activity. However, several studies highlight molecular features and pathways that may influence tumour sensitivity or resistance to fucoidan.
ERK/MAPK Pathway Complexity:
The activity of the ERK (extracellular signal-regulated kinase) pathway is highly variable across cancer types. Some studies show that fucoidan inhibits ERK phosphorylation, reducing tumour growth, while others report ERK activation in response to fucoidan. This suggests that tumours with constitutively active or dysregulated ERK signalling might respond differently, potentially leading to resistance in some contexts16. The complexity and dual roles of ERK (promoting either survival or apoptosis depending on context) make it a possible determinant of resistance.
Survivin and Bcl-2 Expression:
High levels of anti-apoptotic proteins such as Survivin and Bcl-2 are associated with resistance to apoptosis-inducing therapies. Fucoidan reduces Survivin and Bcl-2 expression, tipping the balance towards cell death. Tumours that maintain high levels of these proteins despite fucoidan exposure may be less sensitive or resistant to its effects6.
VEGF and Angiogenesis Pathways:
While fucoidan generally downregulates VEGF and inhibits angiogenesis, some tumour models (e.g., certain hepatocarcinoma lines) show no reduction in VEGF or angiogenesis after fucoidan treatment. This suggests that intrinsic differences in VEGF regulation or alternative angiogenic pathways may confer resistance1.
Cell Line and Tumour Type Differences:
Some cancer cell types, such as specific uveal melanoma lines, appear largely insensitive to certain fucoidan preparations, indicating that intrinsic cellular factors (possibly genetic or epigenetic) can mediate resistance13.
Microenvironment and Receptor Expression:
Fucoidan’s efficacy is partly mediated by its interaction with cell surface receptors (e.g., TLR4, integrins). Variability in receptor expression or downstream signalling (e.g., TLR4 knockdown reduces fucoidan-induced apoptosis) could influence resistance42.
| Marker/Pathway | Role in Resistance | Reference |
|---|---|---|
| ERK/MAPK pathway | Dysregulation may blunt pro-apoptotic effects | 16 |
| Survivin/Bcl-2 | High expression may confer apoptosis resistance | 6 |
| VEGF/angiogenesis | Alternative pathways may maintain angiogenesis | 1 |
| Tumour cell type | Some lines (e.g., uveal melanoma) show insensitivity | 13 |
| TLR4 and other receptors | Low/absent expression may reduce response | 42 |
While no single resistance marker is universally established, tumours with persistent activation of survival pathways (ERK/MAPK, Bcl-2, Survivin), alternative angiogenic mechanisms, or low expression of fucoidan-interacting receptors may be less responsive or resistant to fucoidan. The heterogeneity of response across cell types underscores the need for further research to identify robust predictive markers and tailor fucoidan therapy accordingly.
Preclinical studies have extensively investigated fucoidan’s anti-cancer effects, focusing on in vitro cell models and in vivo animal studies across various cancer types.
Key findings include tumour growth inhibition, apoptosis induction, angiogenesis suppression, and low toxicity.
Apoptosis Induction:
Fucoidan triggers apoptosis in cancer cells via mitochondrial pathways, including:
Angiogenesis Suppression:
Reduces vascular endothelial growth factor (VEGF) expression, critical for tumour blood vessel formation13.
Selective Cytotoxicity:
Effective against breast, colorectal, liver, and lung cancer cells, with minimal impact on normal cells34.
| Cancer Type | Model System | Key Findings |
|---|---|---|
| Hepatocellular Carcinoma | H22 tumour-bearing mice | 42.93% tumour inhibition, reduced serum CEA/VEGF, no toxicity to major organs1. |
| Breast Cancer | 4T1 cell-implanted mice | Reduced tumour volume/weight, increased apoptosis, and suppressed VEGF3. |
| Lung Adenocarcinoma | Lewis lung carcinoma | Repeated fucoidan doses (10 mg/kg) inhibited tumour growth and metastasis2. |
| Ovarian/Cervical Cancer | TOV-112D/HeLa xenografts | Reduced tumour growth; immune modulation (lower IL-6, higher IgG)4. |
Apoptosis Regulation: Modulates Bcl-2/Bax ratio and caspase activation13.
Angiogenesis Inhibition: Suppresses VEGF and disrupts PI3K/AKT/mTOR signalling13.
Immune Modulation: Enhances natural killer (NK) cell activity and reduces pro-inflammatory cytokines (IL-6, TNF-α)14.
Cell Cycle Arrest: Induces G1/S phase arrest via upregulation of p21 and p273.
Low Systemic Toxicity: No significant damage to heart, liver, spleen, or kidneys observed in mice14.
Drug Interaction Potential: Limited inhibition of CYP450 and COMT pathways at high doses, but minimal risk at clinically relevant concentrations4.
Enhanced Efficacy: Fucoidan synergises with paclitaxel, tamoxifen, and topotecan in vitro, improving cancer cell death4.
Reduced Chemo Toxicity: In colorectal and gastric cancer models, fucoidan co-administration reduced chemotherapy-induced fatigue and prolonged treatment duration4.
Preclinical trials demonstrate fucoidan’s broad anti-cancer activity, low toxicity, and potential as an adjunct to chemotherapy. While results are promising, clinical validation is needed to confirm efficacy and safety in humans.
Fucoidan is currently the subject of several ongoing and recent clinical trials, particularly in the context of cancer care and supportive therapy.
| Trial Focus | Phase | Status | Population/Condition | Start Date | Reference |
|---|---|---|---|---|---|
| Fucoidan for fatigue in cancer survivors | N/A | Not yet recruiting | Post-cancer treatment fatigue, inflammation | March 2025 | 1 |
| Fucoidan for preventing chemotherapy-related fatigue | Phase 2 | Begins enrolment | Patients with GI or gynaecological cancers on chemo | March 2025 | 5 |
| Fucoidan as adjunct in locally advanced rectal cancer | Not stated | Completed | Patients undergoing chemoradiotherapy (CCRT) | Recent | 2 |
| Fucoidan as adjunct in metastatic colorectal cancer | Not stated | Completed | Patients on chemo-targeted therapy | Recent | 34 |
Phase 2 Trial (2025):
A randomised, placebo-controlled Phase 2 trial is beginning enrolment in March 2025 to test fucoidan’s effectiveness in preventing chemotherapy-related fatigue in patients with gastrointestinal or gynaecological cancers. The primary objective is to assess fatigue reduction at 8 weeks, with secondary measures of longer-term fatigue and quality of life5.
Feasibility Study in Cancer Survivors (2025):
An 8-week intervention trial at the University of Rochester will evaluate the feasibility and impact of fucoidan supplementation on fatigue, frailty, and inflammation in cancer survivors. This trial is not assigned a formal phase, as it is a feasibility study1.
Recent Completed Trials:
In patients with locally advanced rectal cancer, a double-blind, randomised, placebo-controlled study assessed low molecular weight fucoidan as a supplement to chemoradiotherapy. The trial found improved quality of life and reduced side effects, though the specific phase was not stated2.
In metastatic colorectal cancer, a double-blind, randomised controlled trial evaluated fucoidan as an adjunct to chemotherapy and targeted therapy, reporting improved disease control rates. Again, the phase is not specified, but the design and endpoints are consistent with Phase 2/3 trials34.
Active clinical trials are underway, including at least one Phase 2 trial in 2025 focused on chemotherapy-related fatigue in cancer patients5.
Other ongoing and recent studies are feasibility or adjunctive therapy trials, some without a formal phase designation but generally corresponding to early-phase (Phase 2) research1234.
Fucoidan is being tested both for its supportive care benefits (fatigue, quality of life) and as an adjunct to standard cancer therapies.
No current trials are listed as Phase 3 or Phase 4 as of April 2025.
Current information on active clinical trials can be found on ClinicalTrials.gov.
No specific genetic markers (e.g., SNPs, mutations) have been conclusively identified to predict fucoidan’s efficacy in cancer patients. However, preclinical studies highlight key genes and pathways modulated by fucoidan that may influence its therapeutic response.
Apoptosis-Related Genes:
Angiogenesis and Metastasis Pathways:
Cell Cycle Regulators:
Immune and Inflammatory Mediators:
Tumours with overactive PI3K/AKT/mTOR or JAK-STAT3 signalling may respond better to fucoidan due to its pathway-specific inhibition.
Cancers with dysregulated Bcl-2/Bax ratios or caspase deficiencies might exhibit variable sensitivity.
No clinical studies have yet correlated patient genotypes (e.g., VEGF polymorphisms, PI3K mutations) with fucoidan outcomes.
In vitro evidence suggests pathway dependencies, but in vivo validation in diverse genetic backgrounds is needed.
While fucoidan’s efficacy is mechanistically tied to genes governing apoptosis, angiogenesis, and cell cycle arrest, no patient-specific genetic markers are yet established. Future research should focus on identifying biomarkers within these pathways to personalise fucoidan therapy.
Discover the science-backed potential of beta glucan as an adjunct in cancer therapy. This post delves into the latest research
Explore the emerging world of hydrogen gas (H₂), also known as Brown Gas, and its remarkable potential as an adjunct
Explore the latest scientific insights into vitamin K2 and its promising role in cancer therapy. In this comprehensive blog post,
Website designed in collaboration with Simon Lown for Metabolic Therapy Ltd
Apoptosis, or programmed cell death, is a natural process where cells self-destruct when they are damaged or no longer needed. This is crucial for maintaining healthy tissues and preventing diseases like cancer.
Drugs and supplements that induce apoptosis help eliminate cancerous cells by triggering this self-destruct mechanism, ensuring that harmful cells are removed without damaging surrounding healthy tissue.
Understanding and harnessing apoptosis is vital in the fight against cancer, as it targets the root cause of the disease at the cellular level.
Cell proliferation is the process by which cells grow and divide to produce more cells. While this is essential for growth and healing, uncontrolled cell proliferation can lead to cancer.
Drugs and supplements that inhibit cell proliferation help prevent the rapid multiplication of cancerous cells, slowing down or stopping the progression of the disease.
By targeting the mechanisms that drive cell division, these treatments play a vital role in controlling and potentially eradicating cancer.
Cancer cells often hijack specific biological pathways to grow and spread. Drugs and supplements that target these pathways can disrupt the cancer cell’s ability to survive and multiply.
By focusing on the unique mechanisms that cancer cells use, these treatments can be more effective and cause fewer side effects compared to traditional therapies.
Targeting specific pathways is a key strategy in precision medicine, offering a tailored approach to combat cancer at its core.
Angiogenesis is the process by which new blood vessels form, supplying nutrients and oxygen to tissues. Cancer cells exploit this process to fuel their growth and spread.
Drugs and supplements that inhibit angiogenesis can effectively starve cancer cells by blocking the formation of these new blood vessels.
By cutting off the supply lines that tumors rely on, angiogenesis inhibitors play a crucial role in controlling and potentially shrinking cancerous growths.
Immunotherapy harnesses the power of the body’s immune system to combat cancer. By boosting or restoring the immune system’s natural ability to detect and destroy cancer cells, immunotherapy offers a targeted and effective approach to treatment.
Drugs and supplements that support immunotherapy can enhance the immune response, making it more efficient at identifying and attacking cancer cells.
This innovative approach not only helps in treating cancer but also reduces the risk of recurrence, providing a powerful tool in the fight against this disease.
Inflammation is the body’s natural response to injury or infection, but chronic inflammation can contribute to the development and progression of cancer.
Drugs and supplements with anti-inflammatory properties help reduce inflammation, thereby lowering the risk of cancer and other chronic diseases.
By targeting the inflammatory processes, these treatments can help maintain a healthier cellular environment and prevent the conditions that allow cancer to thrive.
